S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Avidity Biosciences Stock Forecast, Price & News

-0.48 (-3.27%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
322,154 shs
Average Volume
240,611 shs
Market Capitalization
$666.88 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Avidity Biosciences logo

About Avidity Biosciences

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.


Avidity Biosciences (NASDAQ:RNA) Shares Gap Up to $14.70
January 21, 2022 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Hits New 1-Year Low at $16.28
January 18, 2022 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Sees Large Volume Increase
January 14, 2022 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Sets New 1-Year Low at $17.40
January 12, 2022 |  americanbankingnews.com
Avidity Biosciences, Inc. Common Stock (RNA)
January 11, 2022 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$6.79 million
Book Value
$8.16 per share


Net Income
$-44.35 million
Net Margins
Pretax Margin




Free Float
Market Cap
$666.88 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.22 out of 5 stars

Medical Sector

370th out of 1,418 stocks

Pharmaceutical Preparations Industry

172nd out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Avidity Biosciences (NASDAQ:RNA) Frequently Asked Questions

Is Avidity Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avidity Biosciences stock.
View analyst ratings for Avidity Biosciences
or view top-rated stocks.

When is Avidity Biosciences' next earnings date?

Avidity Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Avidity Biosciences

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.68) EPS for the quarter, meeting analysts' consensus estimates of ($0.68). The biotechnology company had revenue of $2.16 million for the quarter, compared to analysts' expectations of $1.50 million. Avidity Biosciences had a negative net margin of 995.70% and a negative trailing twelve-month return on equity of 30.60%.
View Avidity Biosciences' earnings history

What price target have analysts set for RNA?

5 Wall Street analysts have issued 1-year target prices for Avidity Biosciences' stock. Their forecasts range from $36.00 to $59.00. On average, they expect Avidity Biosciences' stock price to reach $49.60 in the next twelve months. This suggests a possible upside of 248.8% from the stock's current price.
View analysts' price targets for Avidity Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Avidity Biosciences' key executives?

Avidity Biosciences' management team includes the following people:
  • Dr. Troy Edward Wilson, Co-Founder & Chairman (Age 52, Pay $132k)
  • Ms. Sarah Boyce, Pres, CEO & Director (Age 49, Pay $823.09k)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 55, Pay $501.34k)
  • Dr. Jae B. Kim FACC, M.D., Chief Medical Officer (Age 51, Pay $340.64k)
  • Prof. Mark E. Davis, Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board (Age 71)
  • Mr. Joseph Baroldi, Chief Operating Officer (Age 43)
  • Dr. W. Michael Flanagan Ph.D., Chief Technical Officer (Age 59)
  • Dr. Arthur A. Levin, Chief Scientific Officer (Age 67) (LinkedIn Profile)
  • Dr. John W. Wallen III, VP of Intellectual Property, Gen. Counsel & Sec. (Age 63)

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Aaron Wealth Advisors LLC (0.46%). Company insiders that own Avidity Biosciences stock include Arthur A Levin and Rtw Investments, Lp.
View institutional ownership trends for Avidity Biosciences

Which major investors are selling Avidity Biosciences stock?

RNA stock was sold by a variety of institutional investors in the last quarter, including Aaron Wealth Advisors LLC.
View insider buying and selling activity for Avidity Biosciences
or view top insider-selling stocks.

How do I buy shares of Avidity Biosciences?

Shares of RNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $14.22.

How much money does Avidity Biosciences make?

Avidity Biosciences has a market capitalization of $666.88 million and generates $6.79 million in revenue each year. The biotechnology company earns $-44.35 million in net income (profit) each year or ($2.45) on an earnings per share basis.

How many employees does Avidity Biosciences have?

Avidity Biosciences employs 82 workers across the globe.

What is Avidity Biosciences' official website?

The official website for Avidity Biosciences is www.aviditybiosciences.com.

Where are Avidity Biosciences' headquarters?

Avidity Biosciences is headquartered at 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company can be reached via email at [email protected].

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.